- Home
- ACON vs KLTO Comparison
ACON vs KLTO Comparison
Compare ACON & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- KLTO
- Stock Information
- Founded
- ACON 2008
- KLTO 2019
- Country
- ACON United States
- KLTO United States
- Employees
- ACON N/A
- KLTO N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- KLTO
- Sector
- ACON Technology
- KLTO
- Exchange
- ACON Nasdaq
- KLTO NYSE
- Market Cap
- ACON 4.8M
- KLTO 7.1M
- IPO Year
- ACON 2022
- KLTO N/A
- Fundamental
- Price
- ACON $6.48
- KLTO $0.18
- Analyst Decision
- ACON Buy
- KLTO
- Analyst Count
- ACON 2
- KLTO 0
- Target Price
- ACON $481.00
- KLTO N/A
- AVG Volume (30 Days)
- ACON 18.4K
- KLTO 33.8M
- Earning Date
- ACON 05-15-2025
- KLTO 05-15-2025
- Dividend Yield
- ACON N/A
- KLTO N/A
- EPS Growth
- ACON N/A
- KLTO N/A
- EPS
- ACON N/A
- KLTO N/A
- Revenue
- ACON $54,601.00
- KLTO N/A
- Revenue This Year
- ACON $212.31
- KLTO N/A
- Revenue Next Year
- ACON N/A
- KLTO N/A
- P/E Ratio
- ACON N/A
- KLTO N/A
- Revenue Growth
- ACON N/A
- KLTO N/A
- 52 Week Low
- ACON $6.20
- KLTO $0.11
- 52 Week High
- ACON $3,499.51
- KLTO $0.99
- Technical
- Relative Strength Index (RSI)
- ACON 34.00
- KLTO N/A
- Support Level
- ACON $6.50
- KLTO N/A
- Resistance Level
- ACON $7.18
- KLTO N/A
- Average True Range (ATR)
- ACON 0.37
- KLTO 0.00
- MACD
- ACON 1.22
- KLTO 0.00
- Stochastic Oscillator
- ACON 14.50
- KLTO 0.00
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.